Abstract
Objective:To evaluate the clinical efficacy of Ganxian recipe (GXR) and lamivudine (LVD) in a two-year treatment of chronic hepatitis B (CHB).Methods: One hundred and twenty patients with CHB were randomly divided into the combinedly treated group (combined group) of 40 CHB patients who were treated with GXR combined with LVD. Another 40 CHB patients were treated with LVD alone (WM group), and still another 40 CHB patients were treated with GXR alone (TCM group). All these cases were randomly controlled and observed for two years.Results: Comprehensive efficacy: Total effective rate of the combined group (complete response and partial response) was 92.5%, while that of the WM group was 67.5% and TCM group 57.5%, respectively, with the difference between them was significant (P<0.01); after treatment, the hepatic functions (AST, ALT, SB) of the three groups were all reduced, and the reduction in the combined group was particularly significant in comparison with the WM group or TCM group,P< 0.05 orP<0.01 respectively, suggesting that the effect in the combined group was better than that in the other two groups; the rate of tyrosine-methionine-aspartate-aspartate (YMDD) virus mutation: it was 7.5% in the combined group, 40.0% in the WM group, and 5.0% in the TCM group; liver fibrosis improvement parameter: after treatment, the results in the combined group got better than those in the other two groups.Conclusion: GXR could inhibit the appearance of YMDD after long-term application of LVD, and combined use has marked synergism.
Similar content being viewed by others
References
Jules L Dienstag, Kurt Jesselbacher. Chronic hepatitis. In: Braunwald E, Fauci AS, Kasper eds. Harrison’s principles of internal medicine. 15th ed. The McGraw-Hill Companies, 2001: 1742–1752.
Shen WS, Yang HZ, Hong Q, et al. Clinical observation of Ganxian recipe matching with lamivudine in treating chronic hepatitis B 31 cases. Chin J Emerg Rescu ICWM 2003; 10(5): 290–292.
Chinese Medical Association Infectious Diseases and Parasitology Society revised. Viral hepatitis prevention and treatment regimen. Chin J Inf Dis 2001; 19(1): 56–62.
Dienstag JL, Schiff ER, Wvight TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256–1263.
Wang JS. Breakthrough of lamivudine in treating chronic hepatitis B and its facing problems. Clin J Hep Biliar 2000; 16 (3): 134–136.
Lai CL, Chien PH, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339: 61–68.
Chen YB, Yang HZ, Xu RY, et al. The immunomodulating effect of Bushen Yangqi Shugan Liangxue Huoxue recipe in treating hepatitis B fibrosis patients. Chin J TCM Bas Med 1999; 4(11): 30–31.
LVD Clinical Use Experts Group. Common understanding of clinical use experts on LVD. Chin J Hepatol 2004; 12 (7): 425.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wei-sheng, S., Hong-zhi, Y., Qi, H. et al. Two-year observation of the clinical efficacy in treating chronic hepatitis B patients with Ganxian recipe and lamivudine. Chin. J. Integr. Med. 11, 5–10 (2005). https://doi.org/10.1007/BF02835740
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02835740